 | |
| Clinical data | |
|---|---|
| Trade names | Yarvitan |
| Other names | Mitratapid; R103757 |
| Routes of administration | By mouth |
| ATCvet code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 55–69% |
| Protein binding | >99.9%[1] |
| Metabolism | Extensiveliver (sulfoxidation);first pass effect |
| Eliminationhalf-life | 6.3 hours (mitratapide), up to 44.7 hours (metabolites) |
| Excretion | Feces (80–90%)[2] |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C36H41ClN8O4S |
| Molar mass | 717.29 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Mitratapide is aveterinary medication used for the treatment of overweight and obese dogs sold under the brand nameYarvitan. Itsmechanism of action involvesinhibition ofmicrosomal triglyceride transfer protein (MTP) which is responsible for the absorption of dietarylipids.[3] Clinical study also suggests that mitratapide may help to reverse insulin resistance in dogs.[4]
The drug was developed byJanssen Pharmaceutica and is chemically related to theantifungal drugs such asitraconazole which were also developed by Janssen.
Mitratapide (under the brand name Yarvitan) was authorized for use in the EU by theEuropean Medicines Agency for helping weight loss in dogs, but it has since been withdrawn from the market in the EU.[5]
 | Thisdrug article relating to thegastrointestinal system is astub. You can help Wikipedia byexpanding it. |
 | Thisveterinary medicine–related article is astub. You can help Wikipedia byexpanding it. |
